CTH Cotec Holdings Corp

Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX
VENTURE:CTH)(OTCQX:CYNAF) today announced that SeeThruEquity, LLC, an
independent investment research and corporate access firm, has initiated equity
research coverage on the Company. The research report is available for viewing
and downloading at www.seethruequity.com. 


Any opinions, judgments, estimates, or forecasts regarding the Company's
historical or predicted performance or operations made by SeeThruEquity, LLC are
theirs alone and do not represent opinions, judgments, estimates, or forecasts
of the Company or its management. The Company does not by its reference to the
research report prepared by SeeThruEquity, LLC imply its endorsement or adoption
of or concurrence with such information, conclusions, or recommendations.


The investment opinions expressed are solely those of SeeThruEquity, LLC.
SeeThruEquity, LLC has not been compensated for the preparation of the report on
the Company by any third party or the Company.


The TSX Venture Exchange Inc. and OTC Markets Group Inc. has not reviewed and
does not accept responsibility for the adequacy or accuracy of this
announcement.


About SeeThruEquity LLC

SeeThruEquity, LLC is an investment research and corporate access firm that
produces high quality research reports on smallcap and microcap companies with
less than $1 billion in market capitalization. The research is unbiased and not
paid-for research. These companies have typically been underserved by the
traditional Wall Street analyst establishment. We are unfettered by any ties to
investment banking or trading, and distribute our high impact research as an
approved contributor on Thomson Reuters One (First Call), CapitalIQ, FactSet,
Zacks and StockTwits, as well as to our own audience of investors from our
corporate website. We also contribute our financial estimates on companies in
our research coverage universe to Thomson Estimates (commonly referred to as
consensus or consensus estimates on the Street).


About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing a convenient and easy
to use sublingual (oral) thin film strip for the acute rescue of "off" motor
symptoms of Parkinson's disease. Over one million people in the U.S. and an
estimated 5 million people globally suffer from Parkinson's disease. Parkinson's
disease is a chronic and progressive neurodegenerative disease that impacts
motor activity, and its prevalence is increasing with the aging of the
population. Based on a recent study and the results of the Company's Global 500
Neurologists Survey, it is estimated that between 25 percent and 50 percent of
patients experience "off" episodes in which they have impaired movement or
speaking capabilities. Current medications only control the disease's symptoms,
and most drugs become less effective over time as the disease progresses.


Cynapsus' drug candidate, APL-130277, is an easy-to-administer, fast-acting
reformulation of apomorphine, which is the only approved drug (in the United
States, Europe, Japan and other countries) to rescue patients from "off"
episodes. Apomorphine is currently primarily available as an injection, which is
inconvenient and painful. Cynapsus is focused on maximizing the value of
APL-130277 by completing pivotal studies in advance of a New Drug Application
("NDA") expected to be submitted in 2016. Cynapsus anticipates a trade sale or
out-licensing to an appropriate global pharmaceutical partner before such an
application is submitted.


More information about Cynapsus (TSX VENTURE:CTH)(OTCQX:CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.


Forward Looking Statements

This announcement contains "forward-looking statements" within the meaning of
applicable Canadian securities legislation. Generally, these forward-looking
statements can be identified by the use of forward-looking terminology such as
"plans", "expects" or "does not expect", "is expected", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that certain
actions, events or results "may", "could", "would", "might" or "will be taken",
"occur" or "be achieved". Forward-looking statements are subject to known and
unknown risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of Cynapsus to be
materially different from those expressed or implied by such forward-looking
statements, including but not limited to those risks and uncertainties relating
to Cynapsus' business disclosed under the heading "Risk Factors" in its Annual
Information Form filed on August 30, 2013 and its other filings with the various
Canadian securities regulators which are available online at www.sedar.com.
Although Cynapsus has attempted to identify important factors that could cause
actual results to differ materially from those contained in forward-looking
statements, there may be other factors that cause results not to be as
anticipated, estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking statements. Cynapsus
does not undertake to update any forward-looking statements, except in
accordance with applicable securities laws.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg@cynapsus.ca


Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams@cynapsus.ca
www.cynapsus.ca

Grafico Azioni Cotec (TSXV:CTH)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Cotec (TSXV:CTH)
Storico
Da Giu 2023 a Giu 2024